LHTC.DE vs. LYMS.DE
LHTC.DE (Lyxor STOXX Europe 600 Healthcare UCITS ETF Acc) and LYMS.DE (Amundi Nasdaq-100 II UCITS ETF Acc) are both exchange-traded funds - LHTC.DE is a Health & Biotech Equities fund tracking the STOXX® Europe 600 Health Care, while LYMS.DE is a Nasdaq-100 fund tracking the Nasdaq 100®. Both are passively managed. Over the past 10 years, LHTC.DE returned 5.88%/yr vs 21.41%/yr for LYMS.DE. At a 0.47 correlation, their price movements are largely independent. LHTC.DE charges 0.30%/yr vs 0.22%/yr for LYMS.DE.
Performance
LHTC.DE vs. LYMS.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LHTC.DE achieves a -2.55% return, which is significantly lower than LYMS.DE's 20.63% return. Over the past 10 years, LHTC.DE has underperformed LYMS.DE with an annualized return of 5.88%, while LYMS.DE has yielded a comparatively higher 21.41% annualized return.
LHTC.DE
- 1D
- 3.03%
- 1M
- 0.27%
- YTD
- -2.55%
- 6M
- -1.03%
- 1Y
- 4.57%
- 3Y*
- 2.35%
- 5Y*
- 5.04%
- 10Y*
- 5.88%
LYMS.DE
- 1D
- -0.86%
- 1M
- 7.96%
- YTD
- 20.63%
- 6M
- 18.72%
- 1Y
- 37.20%
- 3Y*
- 24.71%
- 5Y*
- 18.88%
- 10Y*
- 21.41%
LHTC.DE vs. LYMS.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LHTC.DE Lyxor STOXX Europe 600 Healthcare UCITS ETF Acc | -2.55% | 7.11% | 3.92% | 7.59% | -6.20% | 25.48% | -1.95% | 27.54% | 2.95% | 4.36% |
LYMS.DE Amundi Nasdaq-100 II UCITS ETF Acc | 20.63% | 7.15% | 33.72% | 51.52% | -29.87% | 39.59% | 34.60% | 42.84% | 3.18% | 15.91% |
Correlation
The correlation between LHTC.DE and LYMS.DE is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.14 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.24 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.34 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.45 |
Correlation (All Time) Calculated using the full available price history since Jan 3, 2007 | 0.47 |
Over the past year, the correlation between LHTC.DE and LYMS.DE has dropped to 0.14 - well below their long-term average of 0.47, suggesting their price drivers have been diverging.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LHTC.DE vs. LYMS.DE — Risk / Return Rank
LHTC.DE
LYMS.DE
LHTC.DE vs. LYMS.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Lyxor STOXX Europe 600 Healthcare UCITS ETF Acc (LHTC.DE) and Amundi Nasdaq-100 II UCITS ETF Acc (LYMS.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LHTC.DE | LYMS.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.10 | ||
| Sortino ratioReturn per unit of downside risk | -2.62 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.42 | -0.35 |
| Calmar ratioReturn relative to maximum drawdown | 0.40 | 3.77 | -3.37 |
| Martin ratioReturn relative to average drawdown | 0.89 | 11.23 | -10.35 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| LHTC.DE | LYMS.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.30 | 2.40 | -2.10 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.32 | 0.94 | -0.61 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.38 | 1.08 | -0.70 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.44 | 0.77 | -0.33 |
Drawdowns
LHTC.DE vs. LYMS.DE - Drawdown Comparison
The maximum LHTC.DE drawdown since its inception was -40.53%, smaller than the maximum LYMS.DE drawdown of -50.00%. Use the drawdown chart below to compare losses from any high point for LHTC.DE and LYMS.DE.
Loading charts...
Drawdown Indicators
| LHTC.DE | LYMS.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -40.53% | -50.00% | +9.47% |
Max Drawdown (1Y)Largest decline over 1 year | -12.43% | -10.02% | -2.41% |
Max Drawdown (3Y)Largest decline over 3 years | -26.48% | -26.74% | +0.26% |
Max Drawdown (5Y)Largest decline over 5 years | -26.48% | -31.12% | +4.64% |
Max Drawdown (10Y)Largest decline over 10 years | -26.48% | -31.12% | +4.64% |
Current DrawdownCurrent decline from peak | -11.60% | -0.86% | -10.74% |
Average DrawdownAverage peak-to-trough decline | -9.31% | -8.78% | -0.53% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.67% | 3.37% | +2.30% |
Volatility
LHTC.DE vs. LYMS.DE - Volatility Comparison
Lyxor STOXX Europe 600 Healthcare UCITS ETF Acc (LHTC.DE) has a higher volatility of 5.69% compared to Amundi Nasdaq-100 II UCITS ETF Acc (LYMS.DE) at 4.37%. This indicates that LHTC.DE's price experiences larger fluctuations and is considered to be riskier than LYMS.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LHTC.DE | LYMS.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.69% | 4.37% | +1.32% |
Volatility (6M)Calculated over the trailing 6-month period | 11.67% | 10.99% | +0.68% |
Volatility (1Y)Calculated over the trailing 1-year period | 16.60% | 15.73% | +0.87% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 15.44% | 19.91% | -4.47% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 15.57% | 19.68% | -4.11% |
LHTC.DE vs. LYMS.DE - Expense Ratio Comparison
LHTC.DE has a 0.30% expense ratio, which is higher than LYMS.DE's 0.22% expense ratio.
Dividends
LHTC.DE vs. LYMS.DE - Dividend Comparison
Neither LHTC.DE nor LYMS.DE has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LHTC.DE Lyxor STOXX Europe 600 Healthcare UCITS ETF Acc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LYMS.DE Amundi Nasdaq-100 II UCITS ETF Acc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.65% | 0.69% | 0.76% | 1.09% | 1.18% |
Frequently Asked Questions
LHTC.DE and LYMS.DE have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, LYMS.DE is cheaper at 0.22% per year. The better choice depends on whether you care most about return, fees, risk, or income.
LYMS.DE is cheaper with a 0.22% expense ratio, compared with 0.30% for LHTC.DE.
LHTC.DE is categorized as Health & Biotech Equities, while LYMS.DE is Nasdaq-100. LHTC.DE tracks STOXX® Europe 600 Health Care, while LYMS.DE tracks Nasdaq 100®. Their fees differ too: 0.30% for LHTC.DE and 0.22% for LYMS.DE.
Find the right allocation for LHTC.DE and LYMS.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer